Transdel Targeting Cellulite In ’09 While Finishing Trials For Anti-Pain Drug
This article was originally published in The Rose Sheet
Executive Summary
Transdel Pharmaceuticals is targeting an underserved segment of the cosmeceutical market - anti-cellulite - under its expanded R&D program, and aims to launch its product before year-end